NASDAQ$IRD
Opus Genetics Inc · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Ocuphire reported positive data in a Phase 3 trial for Nyxol eye drops and advanced towards NDA submission.
Ocuphire Pharma announced positive top-line results from the pivotal MIRA-2 Phase 3 trial for Nyxol eye drops in reversal of mydriasis. The company also initiated multiple Phase 2 and 3 clinical trials and is progressing with its second product candidate, APX3330, in Diabetic Retinopathy.
- Reported positive top-line results from the pivotal MIRA-2 Phase 3 trial for Nyxol eye drops in reversal of mydriasis.
- Initiated ZETA-1 Phase 2 trial for APX3330 in Diabetic Retinopathy and Diabetic Macular Edema.
- Initiated Phase 2 VEGA-1 trial evaluating Nyxol and low-dose pilocarpine in Presbyopia.
- Presented positive pre-clinical data supporting APX3330's efficacy at the ARVO virtual Annual Meeting.
Headline financials
Revenue & EPS history
Ocuphire · Revenue · Quarterly
$0
Revenue by segment
Ocuphire · $100K total across 1 segment · Q2 2021
- Collaboration Revenue$100K—100.0%
Forward guidance
Ocuphire anticipates several milestones including top-line data readouts for Presbyopia and Night Vision Disturbances trials, presentation of Phase 3 MIRA-2 results, initiation of a second Phase 3 MIRA-3 trial, and completion of enrollment in the Phase 2 ZETA-1 trial.
Tailwinds
- Top-line data expected end of Q2 2021 for Phase 2 VEGA-1 trial in Presbyopia
- Presenting Phase 3 MIRA-2 results at the ASCRS conference in July
- Top-line data expected end of Q3 2021 for Phase 3 LYNX-1 trial in Night Vision Disturbances
- Planning to initiate second Phase 3 MIRA-3 trial in 2H 2021 for Reversal of Mydriasis
- Completion of enrollment in Phase 2 ZETA-1 trial expected early 2022 for Diabetic Retinopathy and Diabetic Macular Edema
Headwinds
- Success and timing of clinical trials are subject to regulatory submissions.
- Regulatory requirements or developments could impact trial progress.
- Changes to clinical trial designs and regulatory pathways may occur.
- The company may face challenges in obtaining sufficient additional capital.
- Legislative, regulatory, political, and economic developments could affect outcomes.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2021
-3.6%
Avg return
Earnings day
-3.8%
Avg return
5 days after
-3.7%
Avg return
30 days after
42%
14 / 33 earnings
Positive
+16.7%
Q1 2017
Best reaction
-47.3%
Q2 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.2% | -6.1% | -23.7% | |
| Q4 2025 | +1.7% | +5.5% | +15.3% | |
| Q3 2025 | -3.1% | -11.7% | +19.8% | |
| Q2 2025 | +7.4% | +0.9% | +25.5% | |
| Q1 2025 | +7.5% | +4.2% | +2.1% | |
| Q3 2024 | -7.7% | -9.4% | -5.1% | |
| Q2 2024 | -24.7% | -19.9% | -24.1% | |
| Q1 2024 | -14.3% | -11.7% | -13.8% | |
| Q4 2023 | -12.2% | -13.9% | -19.7% | |
| Q3 2023 | +13.4% | +3.5% | -4.9% | |
| Q2 2023 | +0.5% | +0.7% | -3.1% | |
| Q1 2023 | -18.9% | -28.0% | -36.0% | |
| Q4 2022 | +4.2% | +44.2% | +42.5% | |
| Q3 2022 | -2.8% | +13.1% | +52.3% | |
| Q2 2022 | -9.7% | -6.1% | -14.3% | |
| Q1 2022 | +8.5% | +6.5% | +5.5% | |
| Q4 2021 | +11.1% | -9.9% | -35.9% | |
| Q3 2021 | -0.3% | -10.9% | -5.6% | |
| Q2 2021 | -8.5% | -14.7% | -0.6% | |
| Q1 2021 | -7.8% | -5.9% | +17.4% | |
| Q4 2020 | -12.7% | -7.8% | -34.7% | |
| Q3 2020 | +1.4% | -10.8% | -22.4% | |
| Q2 2020 | -1.6% | +1.2% | -25.9% | |
| Q1 2020 | -16.4% | -2.7% | +3.8% | |
| Q3 2019 | -5.9% | -9.3% | -11.2% | |
| Q2 2019 | -47.3% | -49.3% | -54.8% | |
| Q1 2019 | -10.4% | -11.0% | -10.3% | |
| Q2 2018 | +2.7% | +5.4% | +17.0% | |
| Q4 2018 | -2.9% | -3.5% | -4.7% | |
| Q3 2017 | +4.9% | +6.5% | +15.7% | |
| Q2 2017 | +5.9% | -1.6% | +26.5% | |
| Q1 2017 | +16.7% | +29.2% | -10.4% | |
| Q2 2016 | +0.0% | -3.7% | -3.7% | |
| Q1 2014 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro